AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04587583 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WeCareAdvisor
Description: Tailored, internet-based software intended to assess, manage and track behavioral symptoms and their contributing factors and to instruct dementia caregivers in problem solving approaches (tailored strategies for in-home, medication-free behavior management) to address difficult or disruptive behaviors exhibited by the person with dementia. During the testing period participants will refer to the WeCareAdvisor when behavioral challenges occur.
Study NCT04195932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Study NCT00966030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0974 tablet
Description: MK0974 280 mg tablet in one of two treatment periods
Study NCT00966030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: MK0974 liquid filled capsule
Description: MK0974 300 mg liquid filled capsule in one of two treatment periods
Study NCT01425606 — intervention group
Intervention type: OTHER
Intervention: blood test
Description: blood test to measure levels of: sodium, albumin and acid - base status in venous blood.
Study NCT01623024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 20.000 UI/week for 96 weeks
Study NCT01623024 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: Lifestyle counseling for 96 weeks
Study NCT01634451 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bespoke on-line sedation education package
Description: A bespoke on-line education package has been developed and will be accessible by all ICU nursing staff. They will have unique logins and the system will track their use and completion of the education package. There is a small multiple choice assessment at the end of the package.
Study NCT01634451 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedation specific outcome process feedback
Description: Using statistical process charts, the data gathered from the Sedation quality Tools (SQATs) completed each shift by the ICU nurses, will be fed back highlighting sedation specific outcomes e.g. number of over sedated days per 1000 ventilator days.
Study NCT01607528 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Winclove-849
Description: 6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
Study NCT01607528 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A similar looking and tasting powder with no active substances
Study NCT00579709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymus Tissue for Transplantation
Description: 3 Thymoglobulin doses given prior to thymus tx. Atypical subjects given Cyclosporine (Csa) pre-tx. Desired Csa concentration 180-300ng/ml. If post-tx T cell count remained \<4000/cumm Csa weaned over 8 weeks. If T cell >4,000/cumm, Csa held at 180-300ng/ml.~Thymus tissue, donor, \& mother of donor were screened for transplant safety. In operating room, thymic slices were transplanted into quadriceps muscle in 1 or both legs.~Subjects had routine blood research immune evaluations. 2-3 months post-tx, open biopsy of allograft. Immune blood studies continued on surviving subjects until January 2010. Biological Mother: Mother provided blood sample used for DNA extraction, to identify/look for maternal T cell presence in recipient pre-tx, and/or for immune testing post-tx.
Study NCT04164862 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AccuVein AV400 Device Versus Ultrasound-guided Cannulation
Description: Accuvein AV400 device versus Ultrasound guided cannulation
Study NCT01682746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photofrin (porfimer sodium) & photodynamic therapy.
Description: Intravenous (IV) Photofrin~This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity \& light precautions for a minimum of 30 days after the infusion.~Photodynamic Therapy (PDT)~After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time.
Study NCT01634451 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Responsiveness monitoring; novel sedation monitor
Description: Responsiveness monitoring (developed by GE Healthcare) is a novel technology used to monitor patient responsiveness and essentially alert ICU nursing staff when their patients may be over sedated.
Study NCT04610502 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Administration of Equine immunoglobulin anti SARS-CoV-2
Description: The participants will receive premedication with Acetaminophen 500mg PO, Cimetidine300mg IV and Chlortrimeton 10mg IV. Then the investigators will do the Administration of Equine Imunoglobulin anti SARS Cov 2 on day 1 a vial of 10ml of the drug during 1 hour Intravenously. Then the hospitalized participants will be followed until they are discharged.
Study NCT03623971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cataract AI agent
Description: An artificial intelligence to make comprehensive evaluation and treatment decision of different types of cataracts.
Study NCT01132300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Image Guided TENS (Auto-Targeted Neurostimulation, NeMa-st)
Description: Patients will undergo 2 treatments per week during 4 weeks using the device. During the study Patients are allowed to maintain/continue taking medications/ analgesics for pain relief prescribed to them before the study. Medication use will be recorded.
Study NCT02278965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850mg, oral, twice a day for 12 months
Study NCT02278965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: Omega-3 fatty acids 2 capsules (560 mg each) oral, twice a day for 12 months
Study NCT04222842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082
Description: Subjects will receive CM082 orally for two weeks followed by two weeks off in four-week cycles.The total treatment period is tentatively set at 3 cycles (12 weeks).
Study NCT01633099 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: 1. Number of Cycles: 4 cycles.~2. Dose and drug delivery(decitabine):~The 1st cycle: 20 mg/m2, (iv,>1 hour) d1-10 of each 28 day cycle. The 2nd-4th cycle:If bone marrow blast cells≥5%, the following cycle is the same as the 1st cycle.~If bone marrow blast cells\<5%, the following cycle:decitabine 20 mg/m2, (iv,>1h) on d1-5 of each 28 day cycle.~If Grade 4 neutropenia（\<0.5×10E9/L）come arise after 5 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 4 days(20 mg/m2, IV ,>1h, on d1-4 of each 28 day cycle).If Grade 4 neutropenia（\<0.5×10E9/L）come arise after 4 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 3 days(20 mg/m2, IV,>1h, on d1-3 of each 28day cycle).
Study NCT06040216 — intervention group
Intervention type: OTHER
Intervention: optical coherence tomography
Description: We observed the postoperative improvement in EIFL severity with optical coherence tomography
Study NCT02944435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839 Capsules
Description: 3 x 200 mg CB-839 Capsules (Reference Formulation)
Study NCT02944435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CB-839 Tablets
Description: 3 x 200 mg CB-839 Tablets (Test Formulation)
Study NCT01825239 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of measurements during LV pacing during electrophysiology study
Description: During the electrophysiology study, measurements will be obtained while pacing from different left ventricular regions in context to scar as determined by SPECT-CT testing.
Study NCT03877224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
Study NCT03877224 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
Study NCT01589679 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard of care
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
Study NCT01589679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metarsal Dynasplint
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
Study NCT02456961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iontophoresis of riboflavin
Study NCT02456961 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epithelium-off
Study NCT02456961 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal collagen crosslinking
Description: Standard surface UVA irradiation (370 nm, 3 mW/cm2; UFalink, Russian Federation) was then applied at a 5-cm distance for 30 minutes. During UVA exposure, hypotonic riboflavin drops were continued every 2 minutes.
Study NCT02456961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking
Description: Standard surface UVA irradiation (370 nm, 3 mW/cm2; UFalink, Russian Federation) was then applied at a 5-cm distance for 30 minutes. During UVA exposure, hypotonic riboflavin drops were continued every 2 minutes.
Study NCT02456961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: galvanizator, Potok-1
Description: Device for providing iontophoresis procedure
Study NCT02456961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextralink
Description: Riboflavin 0,1% + Dextran T-500
Study NCT02456961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin 0,1%
Study NCT02456961 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UFalink
Description: device for UVA irradiation - providing UVA light - 370 nm, 3 mW/cm2
Study NCT04053569 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Table Grape supplement
Description: 5g/Kg of table grape for four weeks with dietary recommendations along with a strict restriction of fruits and limitation of other foods containing polyphenols.
Study NCT02456961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UFalink
Description: device for UVA irradiation - providing UVA light - 370 nm, 3 mW/cm2
Study NCT03541707 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep TMS Brainsway's H coil
Description: During the treatment trial period all subjects will receive the following dose of TMS: 18 Hz, at 100% RMT, 2 sec pulse train, 20 second inter-train interval, 80 trains, for a total of 57,600 pulses over the complete treatment course. In the placebo group a state of the art sham procedure will be used- the coil is programed to produce the noise and local sensation but with no activation.~EEG Recording is done with and without an acoustic oddball trigger, in order to have both resting state and event related recordings. The evaluation takes approximately 5 minutes.
Study NCT03541707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep TMS Brainsway's H coil
Description: During the treatment trial period all subjects will receive the following dose of TMS: 18 Hz, at 100% RMT, 2 sec pulse train, 20 second inter-train interval, 80 trains, for a total of 57,600 pulses over the complete treatment course. In the placebo group a state of the art sham procedure will be used- the coil is programed to produce the noise and local sensation but with no activation.~EEG Recording is done with and without an acoustic oddball trigger, in order to have both resting state and event related recordings. The evaluation takes approximately 5 minutes.
Study NCT02751164 — intervention group
Intervention type: OTHER
Intervention: Day/time of admission to the critical care unit
Study NCT02411981 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Autogenic drainage
Study NCT04588844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol Recombinant Human Somatropin
Description: Polyethylene glycol recombinant human somatropin will be injected weekly (3mg/per week) from the beginning of preceding menstruation cycle until the day of ovum pickup.
Study NCT00110799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB497115
Description: Approximately 160 subjects will be randomized equally to one of four treatment groups of approximately 40 subjects (A-D). Subjects will receive oral tablets of SB-497115-GR at 30mg, 50 mg, 75 mg or placebo administered once daily for a total of 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
Study NCT00110799 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
Study NCT00827658 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar Wrist Block
Description: Injection medial to Flexor Carpi Ulnaris Tendon at volar proximal wrist crease~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)
Study NCT00827658 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothenar Palm block
Description: Injection at Hook of the Hamate on Palmar surface~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)
Study NCT01995864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CTI-TS
Description: The following briefly describes the three phases of CTI-TS:~Phase 1: Initiation: The client and CTI-TS team formulate a treatment plan that focuses on selected areas identified as crucial for strengthening stability and facilitating the assimilation of the individual into community living.~Phase 2: The Try-Out phase is devoted to testing and adjusting the support systems that have been established in the community.~Phase 3: The final phase, Transfer of Care, is devoted to making any necessary improvements in the network of supports of the individual.
Study NCT03932929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal Adhesive (3M ESPE)
Description: Adhesive system
Study NCT01990872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (20 micrograms/day)
Description: Vitamin D3 (20 micrograms/day)
Study NCT01990872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0 micrograms vitamin D3/day)
Study NCT01956864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.
Study NCT04657562 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus
Description: Prevention of rejection in kidney or liver transplant: a standard immunosuppressive therapy according to international protocols.
Study NCT02637388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oatwell28 Oatwell Original Powder
Study NCT02637388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Breakfast
Description: Isocaloric breakfast without added beta-glucans
Study NCT04657562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Unbound tacrolimus measurement
Description: Unbound tacrolimus measurement in plasma ultrafiltrate.
Study NCT04657562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CYP3A4 and CYP3A5 genotyping
Description: DNA purification and genotyping
Study NCT01411098 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo 3D-CRT
Study NCT01411098 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT
Study NCT01411098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT02892487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swallowing therapy
Description: Patients will undergo active swallowing therapy with a speech and language therapist (twice a week) combined to a detailed program of swallowing auto-exercises (twice a day) from start of radiotherapy to one month after the end.
Study NCT04679103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eculizumab (JSC GENERIUM, Russia)
Description: Eculizumab
Study NCT04808128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drink A + SC
Description: Consumption of energy drink that contains 80mg caffeine and 27g carbohydrates per 250ml together with simple carbohydrates.
Study NCT04808128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drink B + SC
Description: Consumption of soft drink, non-caffeine drink that contains 27g carbohydrates per 250ml together with simple carbohydrates.
Study NCT04808128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drink C + SC
Description: Consumption of soda water, non-caffeine and non-carbohydrate drink together with simple carbohydrates.
Study NCT04808128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drink A + CC
Description: Consumption of energy drink that contains 80mg caffeine and 27g carbohydrates per 250ml together with complex carbohydrates.
Study NCT04808128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drink B + CC
Description: Consumption of soft drink, non-caffeine drink that contains 27g carbohydrates per 250ml together with complex carbohydrates.
Study NCT04808128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drink C + CC
Description: Consumption of soda water, non-caffeine and non-carbohydrate drink together with complex carbohydrates.
Study NCT03941314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supera® Peripheral Stent System
Description: The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
Study NCT03941314 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EverFlex™ Self-Expanding Peripheral Stent System
Description: The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
Study NCT01170819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double balloon catheter
Description: The balloons either side of the cervix are inflated with 50 ml of water. The catheter is removed after 12 hours if spontaneous expulsion has not occurred.
Study NCT01170819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone 10 mg controlled-release vaginal insert
Description: Vaginal insert is placed in the posterior vaginal fornix for a maximum period of 24 hours.
Study NCT00819949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs through position controlled trajectories that mimic normal human gait patterns. This is accomplished by utilizing high quality computer-controlled motors that are precisely synchronized with the speed of the treadmill. The hip and knee joint angles are controlled in real time by software to achieve kinematically correct stepping behaviors. Each of the four motor-driven joints is individually controlled to correspond precisely to the desired joint angle trajectories. This system assures a precise match between the speed of the limb trajectory and the treadmill. In addition, sensors in the motors provide an indirect indicator of the amount of effort the patient is generating to achieve walking in an upright posture.
Study NCT03983785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: In pilates group: Pilates training twice a week for 6 weeks.
Study NCT03983785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic taping
Description: Elastic taping group: Elastic taping application after the pilates training twice a week for 6 weeks Wait List